Projet ENTRAIN (Horizon 2020, appel à projets 2018)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

Neurological diseases cause enormous suffering and a great economic burden. Almost 20 million Europeans are affected by the most frequently occurring and disabling disease entities, such as stroke, Alzheimer’s disease (AD), or multiple sclerosis (MS), and these numbers do not include the large group of rare diseases that affect the CNS. Overall, the annual costs for patient care amount to 400 billion Euros. Common features of many neurological diseases are a vascular pathology with impaired blood-brain barrier (BBB) function or with reduced blood flow and inflammatory changes. As the two are often associated, disentangling their intricate and mutual relationship is a major task for translational neuroscience that could improve the treatment of many neurological diseases. At the cellular level, key players are brain endothelial cells as the building blocks of cerebral vessels and macrophages as the main inflammatory cells of the brain. Recent discoveries indicate that endothelial cells and brain macrophages are in intimate contact and closely interact. However, there is a huge gap of knowledge regarding the specific mode and the consequences of these interactions. Therefore, in-depth analyses of the molecular mechanisms involved are essential to identify and understand key features of macrophage-endothelial cross-talk, and exploitation of this information for the development of treatments of neurological diseases. ENTRAIN will undertake this task, using novel and emerging technologies, such as cutting-edge chemoproteomics, unique genetic and viral tools for targeting of defined cell populations, and high resolution intravital imaging. By characterising the pas de deux of endothelial cells and macrophages at the functional and morphological level, we will lay the foundation for better therapies for neurological diseases. The results will impact on the understanding of neuroinflammation, but also on the rarefaction of vessels.

Mots clés : stroke, multiple sclerosis, alzheimer s disease, endothelial cells, macrophages, microglia, neurological diseases, blood brain barrier, experimental autoimmune encephalomyelitis

Participants :
- Spanish National Research Council (Espagne) — Partner, beneficiary, Recherche, subvention : 250904.88 €
- Mario Negri Institute for Pharmacological Research (Italie) — Partner, beneficiary, Recherche, subvention : 261499.68 €
- University of Helsinki (Finlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 280805.76 €
- Hungarian Academy of Sciences (Hongrie) — Partner, beneficiary, Recherche, subvention : 229715.28 €
- PolyGene (Suisse) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Institut national de la santé et de la recherche médicale (France) — Partner, beneficiary, Recherche, subvention : 274802.04 €
- Amsterdam University Medical Centers (Pays-Bas) — Partner, beneficiary, Recherche, subvention : 265619.88 €
- Brendinn therapeutics b.v. (Pays-Bas) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Lübeck (Allemagne) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 505576.8 €
- University of Freiburg (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 252788.4 €
- Boehringer Ingelheim (Germany) (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Board of the Swiss Federal Institutes of Technology (Suisse) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 281276.64 €
- University of Münster (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 252788.4 €
- University of Brescia (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 261499.68 €
- Stroke alliance for europe (Belgique) — Partner, organization partner, Autres, subvention : 0.0 €
- University of Bern (Suisse) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 281276.64 €
- Dualsystems biotech ag (Suisse) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Leiden University (Pays-Bas) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Mimetas (Netherlands) (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 265619.88 €
- Incontinentia pigmenti (France) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €